




CytImmune Sciences have announced 
the preliminary data of a National 
Cancer Institute conducted Phase 1 trial 
of its gold-based treatment, CYT-6091 
(Aurimune), CytImmune is a clinical 
stage nanomedicine company  
focused on the development and 
commercialization of multifunctional, 
tumor-targeted therapies harnessing 
the unique properties of gold 
nanoparticles. CYT-6091 (Aurimune), 
CytImmune’s lead drug compound, is 
recombinant human tumor necrosis 
factor alpha (TNF) bound to the surface 
of 27 nanometer PEGylated colloidal 
gold nanoparticles. While TNF’s tumor 
killing properties are well documented, 
its clinical use has been severely 
limited due to unacceptable toxicities.
The Phase 1 clinical trial was designed 
to investigate whether Aurimune will 
perform identically in humans as it did 
in preclinical studies and companion 
animals and also the whether the fever 
side effect observed in preclinical 
studies can be easily managed. 
Preliminary data from the Phase 1 
study indicates that CYT-6091 is seen  
in tumors, but not in healthy tissue; a 
positive result. To date the drug has  
had no effect on renal, liver or immune 
function and no unexpected serious 
adverse events have been reported. 




In its search for higher-value products, Canada’s 
paper industry is supporting research to develop 
paper that can detect or kill E. coli in grocery 
stores and water sources, and airborne germs in 
hospitals and gold nanoparticles are, perhaps not 
surprisingly, a key part of the technology.
The partnership of academics and industry is called 
the Sentinel Bioactive Paper Network. The group 
is funded by the Natural Sciences and Engineering 
Research Council, Canada Foundation for  
Innovation, the Ontario 
government, and the  
















Gold continues to be one of the most studied 
materials at the nanoscale ... seven of the  
JefJm[djoCeij7YY[ii[Z7hj_Yb[i in the 
Journal of Physical Chemistry during 2006 













































A new patent application from US researcher 
Kattesh Katti describes a new preparation 
technique for producing gold nanoparticles 
(WO2007027978 A2). The major advantage 
claimed is that gold nanoparticles may be 
produced in much less time than traditional 
preparations, and at temperatures of less 
than about 30oC. The basic method involves 
reacting the gold salt with a phosphino amino 
acid. The full patent can be accessed free of 
charge via http://ep.espacenet.com3
One of the ﬁnal chapters of any successful 
conference is the eventual publication of its 
content. It is excellent news then that the 
special issue of Materials Science and 
Engineering B, which is devoted to the latest 
developments in the science and technology  
of gold at the nanoscale, has just been 
published. The papers were selected from 
presentations made at the Gold 2006 
conference held in Limerick, Ireland.  
The special issue, Materials Science and 
Engineering B 140 (2007) 137, was edited  
by Michael Cortie, Professor & Director,  
UTS Institute for Nanoscale Technology, 
University of Technology Sydney, Australia 3  
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